Skip to main content

Fiscal Wizard · Single-issue tearsheet

LAB / Jun 22, 2026 Run #7607

LAB

Standard BioTools Inc.

Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates through Proteomics and Genomics segments. Its proteomics and genomics include instruments, consumables, and assays for clinical and diagnostic uses. The company also provides SomaScan platform that enables researchers to measure proteins simultaneously and provides deep insights into biological processes and disease mechanisms; CyTOF technology platform that uses metal-tagged antibodies and time-of-flight mass spectrometry to eliminate signal interference and expand multiplexing capabilities; Hyperion, a spatial biology platform, which unlocks deeper insights into tissue organization by preserving spatial context while enabling high-dimensional molecular and proteomic analysis; and Biomark X9 system that redefines high-throughput genomics for quantitative polymerase chain reaction applications. The company sells its instruments and consumables for research use only to academic research institutions, translational research and medicine centers, cancer centers, and clinical research laboratories, as well as biopharmaceutical, biotechnology, and plant and animal research companies. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in November 2001. Standard BioTools Inc. was incorporated in 1999 and is headquartered in Boston, Massachusetts.

Composite verdict

F 13.4 / 100
Bearish setup · Trend Following 19 drivers · 6 gates blocking
  • Relative Strength vs SPY
  • Rate of Change
  • TRIX Zero-Line
Consider long put target Δ ~0.70 · ~35 DTE Bearish setup, Grade A → ITM put target

Industry rank 99th of 141 in Medical Devices

rescore-sweep
Technical synthesisRegime: volatile downtrend
Bull 0%Evidence: High · 21 signals100% Bear
Momentum Bearish 2Mean-reversion Neutral 49

No notable composite patterns — the signals don't cluster into a named setup right now.

Where value comes fromMargin of safety +34%

Earnings power doesn't cover the capital structure (high debt) — the EPV decomposition isn't meaningful for this name.

Fundamentals Weak

26.8 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
EPS Growth (YoY) 100
Free Cash Flow Yield 0
Margin of Safety 100
Revenue Growth (YoY) 0
EV/Sales 75
Inventory Turnover 0

Technicals Bearish

0.0 / 100

Bearish setup leads (Relative Strength vs SPY, Rate of Change, TRIX Zero-Line); bulls gated by guards. · 43 signals shown.

Strongest
Weakest
Rate of Change 8
Relative Strength vs SPY 15
TRIX Zero-Line 17

Risk Gates

6 blocking 4 caution

6 guards active, 16 signals gated.

Altman Z-Score Blocking

Bottom-band Altman Z blocks bullish signals — distress risk.

Interest Coverage Blocking

Weak interest coverage blocks bullish signals — debt-service risk.

Piotroski F-Score Blocking

Bottom-band Piotroski F blocks bullish signals — fundamental-quality risk.

MA Crossover Blocking

Blocks counter-regime signals only when the MA crossover agrees with the long-term regime.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for LAB.